Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer

Corcept Therapeutics (CORT) has submitted a new drug application (NDA) to the FDA for relacorilant, in combination with nab-paclitaxel, for the treatment of platinum-resistant ovarian cancer. This submission is based on positive Phase III ROSELLA study data, which demonstrated improved progression-free survival, and represents a strategic effort to broaden CORT's market presence beyond its sole marketed drug, Korlym. The company had previously filed an NDA for relacorilant in hypercortisolism, and CORT shares have already seen a 44.4% year-to-date increase.

Analysis

Corcept Therapeutics has achieved a significant clinical milestone by submitting a New Drug Application (NDA) to the FDA for its lead candidate, relacorilant, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. This submission is supported by positive pivotal Phase III ROSELLA study data, which met its primary endpoint of improved progression-free survival. This development is a crucial step in the company's strategy to diversify away from its single commercial product, Korlym, which reported a 7.1% year-over-year sales increase to $157.2 million in the first quarter of 2025. The company is concurrently advancing relacorilant for a separate indication, hypercortisolism, with a PDUFA target action date set for December 30, 2025, creating two distinct potential revenue streams for its lead asset. The market has responded positively to this progress, with CORT shares rallying 44.4% year-to-date, far outpacing the industry's 4.1% rise. However, despite these positive developments and strong stock performance, the article flags a significant counterpoint by noting the stock currently carries a Zacks Rank #5 (Strong Sell), indicating potential underlying concerns or valuation issues that contrast with the operational momentum.

Key Decisions for Investors

• Investors should view the successful Phase III ROSELLA data and subsequent NDA filing as a material de-risking event for Corcept's pipeline, validating the potential of relacorilant beyond its initial hypercortisolism indication.
• The primary catalyst to monitor is the regulatory decision for relacorilant in hypercortisolism, with the PDUFA date of December 30, 2025, representing a major binary event that could significantly re-rate the stock.
• Despite strong clinical news, exercise caution due to the conflicting signal of a Zacks Rank #5 (Strong Sell) and the stock's substantial 44.4% year-to-date appreciation, which may already price in much of the positive outlook.
• The investment thesis hinges on successful pipeline execution to mitigate single-product dependency on Korlym; therefore, any setbacks in the FDA review process for either of relacorilant's pending applications would pose a significant risk to future growth.